Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus.
Ontology highlight
ABSTRACT: Hypoglycaemia is a common side-effect of diabetes therapies, particularly insulin, and imposes a substantial burden on individuals and healthcare systems. Consequently, regulatory approval of newer basal insulin (BI) therapies has relied on demonstration of a balance between achievement of good glycaemic control and less hypoglycaemia. Randomized controlled trials (RCTs) are the gold standard for assessing efficacy and safety, including hypoglycaemia risk, of BIs and are invaluable for obtaining regulatory approval. However, their highly selected patient populations and their conditions lead to results that may not be representative of real-life situations. Real-world evidence (RWE) studies are more representative of clinical practice, but they also have limitations. As such, data both fro
SUBMITTER: Frier BM
PROVIDER: S-EPMC6767397 | biostudies-literature | 2019 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA